Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Fish Oil Derived Omega 3 Fatty Acids Suppress Adipose NLRP3 Inflammasome Signaling in Human Obesity

Lee KR., Midgette Y., Shah R.

Clinical Trial on Type 2 Diabetes, published in J Endocr Soc (2019) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
J Endocr Soc (2019)
Reported sample size
—
Source database
Europe PMC
PMID
30788452
PMCID
PMC6371080
DOI
10.1210/js.2018-00220
Citations
42

Abstract (original English)

Context The NRLP3 inflammasome is a multiprotein danger-sensing complex that serves as a critical link between obesity-related adipose inflammation and insulin resistance and has been shown in animal models to be inhibited by fish oil-derived long chain omega-3 polyunsaturated fatty acids ( n -3 PUFA). Objective We conducted a clinical trial and in vitro experiments to test our hypothesis that n -3 PUFA suppress NLRP3 inflammasome in human obesity through downregulation of inflammasome gene expression in adipocytes and macrophages. Design Placebo-controlled clinical trial and in vitro coculture experiments with primary human adipocytes (from biopsy specimens) and human THP-1 monocyte-derived macrophages treated with eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) vs vehicle control. Setting General community, research laboratory. Patients and other participants Obese (body mass index ≥ 30 kg/m 2 ), nondiabetic males and females age 18 to 50. N = 25. Interventions Clinical trial: Eight-week treatment with 4 g Lovaza (EPA and DHA) or placebo. Cells culture: EPA and/or DHA at 100 µg/mL or vehicle control in culture medium. Main outcome measures Adipose tissue or adipocyte/macrophage mRNA expression of IL-1 β and IL-18 and circulating IL-18 levels. Results Treatment of obese human subjects with fish oil supplements reduced expression of adipose inflammatory genes incl

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research